AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19
VANCOUVER, British Columbia and INDIANAPOLIS – AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.
Within one week of receiving a blood sample from one of the first U.S. patients who recovered from COVID-19, AbCellera screened over 5 million immune cells looking for ones that produced functional antibodies that helped the patient neutralize the virus and recover from the disease. From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported. The next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2. Many of these antibodies will be expressed in collaboration with partners at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and pending agreement with NIAID will be tested for their ability to neutralize the virus.
“AbCellera’s platform has delivered, with unprecedented speed, by far the world’s largest panel of anti-SAR-CoV-2 antibodies,” said Carl Hansen, Ph.D., CEO of AbCellera. “In 11 days, we’ve discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world’s leading biopharmaceutical companies. We’re deeply impressed with the speed and agility of Lilly’s response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak.”
“With the number of cases rapidly increasing all over the world, doctors and patients are seeking a therapeutic intervention that can speed their recovery or prevent the disease. Lilly is committed to playing our part to bring innovation to patients amidst this global outbreak,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. “We’ve partnered with AbCellera because we’re impressed with the speed and quality of their efforts. We are moving at top speed to create a potential treatment to help patients. While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months.”
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution. If successful, Lilly is ready to work with global regulators to bring a treatment to patients.
About AbCellera Biologics Inc.
AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. AbCellera was founded in 2012, and completed a Series A financing round in 2018, which was led by DCVC Bio. For more information, visit www.abcellera.com.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and AbCellera, and reflects Lilly’s current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, please see Lilly’s most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Approved for Public Release, Distribution Unlimited
Jessica Yingling, Ph.D., email@example.com, (858) 344-8091 (AbCellera Media)
Kevin Heyries, Ph.D., firstname.lastname@example.org, (604) 559-9005 (AbCellera Investors)
Nicole Hebert; Nicole_Hebert@lilly.com; (317) 701-9984 (Lilly Media)
Kevin Hern; email@example.com; (317) 277-1838 (Lilly Investors)